Affordable Access

deepdyve-link
Publisher Website

Over the counter low-dose cannabidiol: A viewpoint from the ACRE Capacity Building Group.

Authors
  • Hallinan, Christine Mary1, 2
  • Eden, Edward3
  • Graham, Myfanwy3, 4
  • Greenwood, Lisa-Marie5
  • Mills, Jessica6
  • Popat, Amirali7
  • Truong, Linda3, 8, 9
  • Bonomo, Yvonne1, 10
  • 1 Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, VIC, Australia. , (Australia)
  • 2 Department of General Practice, Melbourne Medical School, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, VIC, Australia. , (Australia)
  • 3 School of Medicine and Public Health, Faculty of Health and Medicine, The University of Newcastle, Callaghan, NSW, Australia. , (Australia)
  • 4 Hunter Medical Research Institute, Faculty of Health and Medicine, The University of Newcastle, Callaghan, NSW, Australia. , (Australia)
  • 5 School of Psychology, Australian National University, Canberra, ACT, Australia. , (Australia)
  • 6 School of Psychology, Illawarra Health and Medical Research Institute (IHMRI), Faculty of the Arts Social Sciences and Humanities, University of Wollongong, Wollongong, NSW, Australia. , (Australia)
  • 7 School of Pharmacy, Faculty of Health and Behavioural Sciences, The University of Queensland, Woolloongabba, QLD, Australia. , (Australia)
  • 8 Department of Neurology, Sydney Children's Hospital Randwick, Sydney, NSW, Australia. , (Australia)
  • 9 School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia. , (Australia)
  • 10 Department of Addiction Medicine, St Vincent's Hospital Melbourne, VIC, Australia. , (Australia)
Type
Published Article
Journal
Journal of psychopharmacology (Oxford, England)
Publication Date
Jun 01, 2022
Volume
36
Issue
6
Pages
661–665
Identifiers
DOI: 10.1177/02698811211035394
PMID: 34344208
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Amidst growing global acceptance of medicinal cannabinoids as a potential therapeutic interest in cannabidiol (CBD) is increasing. In Australia in 2020, a government inquiry examined the barriers that the public are experiencing in accessing medicinal cannabis. A number of recommendations to improve access were made. In response to these recommendations, the Australian therapeutics regulatory authority down-scheduled CBD from Prescription Only (Schedule 4) to Pharmacist Only (Schedule 3). As a group of early to mid-career researchers of the Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE), we propose some considerations in relation to over-the-counter availability of CBD and opportunities to improve knowledge about its potential therapeutic benefits alongside its increased uptake.

Report this publication

Statistics

Seen <100 times